Clearbridge Investments LLC Has $344.89 Million Stock Position in Haleon plc (NYSE:HLN)

Clearbridge Investments LLC lifted its position in shares of Haleon plc (NYSE:HLN - Free Report) by 8.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,753,987 shares of the company's stock after purchasing an additional 3,307,009 shares during the quarter. Clearbridge Investments LLC owned approximately 0.91% of Haleon worth $344,888,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of HLN. Cultivar Capital Inc. acquired a new position in shares of Haleon in the 2nd quarter valued at $40,000. Allspring Global Investments Holdings LLC bought a new stake in Haleon in the first quarter valued at $43,000. GAMMA Investing LLC raised its stake in Haleon by 151.3% during the first quarter. GAMMA Investing LLC now owns 6,106 shares of the company's stock worth $52,000 after acquiring an additional 3,676 shares in the last quarter. Pinnacle Bancorp Inc. lifted its holdings in shares of Haleon by 29.8% during the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company's stock valued at $53,000 after acquiring an additional 1,421 shares during the period. Finally, Hexagon Capital Partners LLC boosted its stake in shares of Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company's stock valued at $55,000 after purchasing an additional 2,677 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Trading Up 1.0 %

Haleon stock traded up $0.11 during midday trading on Tuesday, hitting $10.69. 18,440,366 shares of the stock were exchanged, compared to its average volume of 5,056,163. The company has a fifty day simple moving average of $9.97 and a two-hundred day simple moving average of $8.97. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $48.81 billion, a PE ratio of 35.63, a P/E/G ratio of 3.12 and a beta of 0.26. Haleon plc has a 52 week low of $7.70 and a 52 week high of $10.80.

Haleon (NYSE:HLN - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The firm had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period in the prior year, the company earned $0.08 earnings per share. Equities research analysts anticipate that Haleon plc will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were given a dividend of $0.0514 per share. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend was Friday, August 16th. Haleon's dividend payout ratio (DPR) is 33.33%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. The Goldman Sachs Group lowered shares of Haleon from a "buy" rating to a "neutral" rating in a report on Tuesday, August 6th. Morgan Stanley lifted their price target on Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a report on Friday, September 20th. Finally, Berenberg Bank started coverage on shares of Haleon in a report on Tuesday, August 6th. They set a "buy" rating on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.